寡转移膀胱癌手术治疗现状与争议

薛学义; 许宁; 柯志滨

doi:10.13201/j.issn.1001-1420.2019.10.017

寡转移膀胱癌手术治疗现状与争议

- 福建医科大学附属第一医院泌尿外科(福州, 350005)

详细信息

通讯作者: 薛学义,E-mail:xuexueyi@fjmu.edu.cn

中图分类号: R737.14

收稿日期: 2018-11-04

Current status and controversy of surgical treatment for oligometastatic bladder cancer

- Department of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China

More Information

Corresponding author: XUE Xueyi, E-mail: xuexueyi@fjmu.edu.cn

Received Date: 04 November 2018

摘要

摘要: 膀胱癌（BCa）是发病率第2位的泌尿男生殖系恶性肿瘤，一旦发生转移，预后极差。目前转移性膀胱癌（mBCa）的标准治疗方案为基于顺铂的联合系统性化疗，但其治疗反应率及生存率较低，大部分患者化疗后仍会出现疾病进展。研究显示，寡转移膀胱癌行减瘤性膀胱全切除术或转移灶切除术可为部分患者提供生存获益。但现有研究较少且均为回顾性研究，寡转移膀胱癌的概念与诊断标准尚未得到统一，仍需要进一步前瞻性随机对照研究探索寡转移膀胱癌诊断标准及外科手术治疗的可行性、有效性及手术时机。
- 寡转移 /
- 膀胱癌 /
- 膀胱全切除术 /
- 转移灶切除术
Abstract: Bladder cancer(BCa) is the second common urinary and genital carcinoma in males. The prognosis of BCa is poor once metastasis occurs. Currently, the standard treatment for metastatic bladder cancer(mBCa) is systemic combination chemotherapy based on cisplatin. However, the treatment response rate and survival rate are low, and most patients still experience disease progression after chemotherapy. Previous studies indicated that cytoreduced total cystectomy and metastasectomy might provide survival benefits for patients with oligometastatic bladder cancer. However, there are few studies related to oligometastatic bladder cancer currently and all of them are retrospective. Besides, there is no consensus on the concept and diagnostic criteria of oligometastatic bladder cancer. Further prospective randomized controlled studies are needed to explore the diagnostic criteria of oligometastatic bladder cancer and the feasibility, effectiveness and optimal timing of surgical management.
- oligometastasis /
- bladder cancer /
- total cystectomy /
- metastasectomy

HTML全文

参考文献(33)

[1]	Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185countries[J].CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Rosenberg J E, Carroll P R, Small E J.Update on chemotherapy for advanced bladder cancer[J].J Urol, 2005, 174(1):14-20.
[3]	Siegel R, Ma J, Zou Z, et al.Cancer statistics, 2014[J].CA Cancer J Clin, 2014, 64(1):9-29.
[4]	Bajorin D F, Dodd P M, Mazumdar M, et al.Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy[J].JClin Oncol, 1999, 17(10):3173-81.
[5]	Dash A, Galsky M D, Vickers A J, et al.Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder[J].Cancer, 2006, 107(3):506-513.
[6]	Cowles R S, Johnson D E, McMurtrey M J.Long-term results following thoracotomy for metastatic bladder cancer[J].Urology, 1982, 20(4):390-392.
[7]	Hellman S, Weichselbaum R R.Oligometastases[J].JClin Oncol, 1995, 13(1):8-10.
[8]	Muraro E, Furlan C, Avanzo M, et al.Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer[J].Front Immunol, 2017, 8:1476.
[9]	Hu F, Xu J, Zhang B, et al.Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations[J].Clin Lung Cancer, 2019, 20(1):e81-e90.
[10]	Boeri L, Sharma V, Karnes R J.Radiotherapy for newly diagnosed oligometastatic prostate cancer[J].Lancet, 2018, 392(10162):2327-2328.
[11]	Kim M Y, Oskarsson T, Acharyya S, et al.Tumor selfseeding by circulating cancer cells[J].Cell, 2009, 139(7):1315-1326.
[12]	Mertens L S, Horenblas S.Bladder cancer:oligometastases and imaging[J].Nat Rev Urol, 2017, 14(9):513-514.
[13]	Kim T, Ahn J H, You D, et al.Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer[J].Clin Genitourin Cancer, 2015, 13(4):e297-304.
[14]	Ogihara K, Kikuchi E, Watanabe K, et al.Can urologists introduce the concept of"oligometastasis"for metastatic bladder cancer after total cystectomy?[J].Oncotarget, 2017, 8(67):111819-111835.
[15]	Gómez De Lia1o A, Duran I.The continuing role of chemotherapy in the management of advanced urothelial cancer[J].Ther Adv Urol, 2018, 10(12):455-480.
[16]	Bamias A, Tzannis K, Harshman L C, et al.Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract:a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium(RISC)[J].Ann Oncol, 2018, 29(2):361-369.
[17]	Scher H I.A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma:a cooperative group study[J].J Urol, 1992, 148(5):1625-1626.
[18]	von der Maase H, Sengelov L, Roberts J T, et al.Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer[J].J Clin Oncol, 2005, 23(21):4602-4608.
[19]	Bellmunt J, von der Maase H, Mead G M, et al.Randomized phaseⅢstudy comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy:EORTC Intergroup Study 30987[J].J Clin Oncol, 2012, 30(10):1107-1113.
[20]	Sternberg C N, de Mulder P H, Schornagel J H, et al.Randomized phaseⅢtrial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin(MVAC)chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:European Organization for Research and Treatment of Cancer Protocol no.30924[J].J Clin Oncol, 2001, 19(10):2638-2646.
[21]	Galsky M D, Domingo-Domenech J, Sfakianos J P, et al.Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease:Who, How, When, and Why?[J].J Clin Oncol, 2016, 34(29):3495-3498.
[22]	Seisen T, Sun M, Leow J J, et al.Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder:A Propensity Score-Weighted Analysis From the National Cancer Data Base[J].J Clin Oncol, 2016, 34(29):3529-3536.
[23]	Dong F, Shen Y, Gao F, et al.Prognostic value of sitespecific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer:apopulationbased study[J].Cancer Manag Res, 2017, 9:611-626.
[24]	Abe T, Kitamura H, Obara W, et al.Outcome of metastasectomy for urothelial carcinoma:a multi-institutional retrospective study in Japan[J].J Urol, 2014, 191(4):932-936.
[25]	Iwamoto H, Izumi K, Shimura Y, et al.Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma[J].Anticancer Res, 2016, 36(10):5557-5561.
[26]	Faltas B M, Gennarelli R L, Elkin E, et al.Metastasectomy in older adults with urothelial carcinoma:Population-based analysis of use and outcomes[J].Urol Oncol, 2018, 36(1):9.e11-9.e17.
[27]	Siefker-Radtke A O, Walsh G L, Pisters L L, et al.Is there a role for surgery in the management of metastatic urothelial cancer?The M.D.Anderson experience[J].J Urol, 2004, 171(1):145-148.
[28]	Lehmann J, Suttmann H, Albers P, et al.Surgery for metastatic urothelial carcinoma with curative intent:the German experience(AUO AB 30/05)[J].Eur Urol, 2009, 55(6):1293-1299.
[29]	Matsuguma H, Yoshino I, Ito H, et al.Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?[J].Ann Thorac Surg, 2011, 92(2):449-453.
[30]	Abe T, Shinohara N, Harabayashi T, et al.Impact of multimodal treatment on survival in patients with metastatic urothelial cancer[J].Eur Urol, 2007, 52(4):1106-1113.
[31]	Herr H W, Donat S M, Bajorin D F.Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer[J].J Urol, 2001, 165(3):811-814.
[32]	Kanzaki R, Higashiyama M, Fujiwara A, et al.Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma[J].Interact Cardiovasc Thorac Surg, 2010, 11(1):60-64.
[33]	Luzzi L, Marulli G, Solli P, et al.Long-Term Results and Prognostic Factors of Pulmonary Metastasectomy in Patients with Metastatic Transitional Cell Carcinoma[J].Thorac Cardiovasc Surg, 2017, 65(7):567-571.